The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment

References

• Mantovani A, Allavena P, Sica A, . Cancer-related inflammation. Nature 2008;454:436–444.
   PubMed Web of Science ®Google Scholar
• Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009;9:15–27.
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Gloghini A, Pinto A, . The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 2010;221:248–263.
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A, Gattei V, . Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood 1995;85:780–789.
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A, Gruss HJ, . CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Am J Pathol 1995;147:912–922.
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Rapana’ B, Olivo K, . IRF4 is modulated by CD40L and by apoptotic and anti-proliferative signals in Hodgkin lymphoma. Br J Haematol 2010;148:115–118.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Stanelle J, Hansmann ML, . Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol 2009;4:151–174.
   PubMed Web of Science ®Google Scholar
• Timens W, Visser L, Poppema S. Nodular lymphocyte predominance type of Hodgkin's disease is a germinal center lymphoma. Lab Invest 1986;54:457–461.
   PubMed Web of Science ®Google Scholar
• Poppema S. The nature of the lymphocytes surrounding Reed-Sternberg cells in nodular lymphocyte predominance and in other types of Hodgkin's disease. Am J Pathol 1989;135:351–357.
   PubMed Web of Science ®Google Scholar
• Kraus MD, Haley J. Lymphocyte predominance Hodgkin's disease: the use of bcl-6 and CD57 in diagnosis and differential diagnosis. Am J Surg Pathol 2000;24:1068–1078.
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A, Aldinucci D, . Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease. Br J Haematol 2002;117:366–372.
   PubMed Web of Science ®Google Scholar
• Nam-Cha SH, Roncador G, Sanchez-Verde L, . PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma. Am J Surg Pathol 2008;32:1252–1257.
   PubMed Web of Science ®Google Scholar
• Marshall NA, Christie LE, Munro LR, . Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004;103:1755–1762.
   PubMed Web of Science ®Google Scholar
• Yamamoto R, Nishikori M, Kitawaki T, . PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008;111:3220–3224.
   PubMed Web of Science ®Google Scholar
• Schreck S, Friebel D, Buettner M, . Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol 2009;27:31–39.
   PubMed Web of Science ®Google Scholar
• Hsi ED. Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment. Leuk Lymphoma 2008;49:1668–1680.
   PubMed Web of Science ®Google Scholar
• Dave SS, Wright G, Tan B, . Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159–2169.
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Salvado MT, . Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005;11:1467–1473.
   PubMed Web of Science ®Google Scholar
• Steidl C, Lee T, Shah SP, . Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010;362:875–885.
   PubMed Web of Science ®Google Scholar
• DeVita VT Jr, Costa J. Toward a personalized treatment of Hodgkin's disease. N Engl J Med 2010;362:942–943.
   PubMed Web of Science ®Google Scholar
• Diehl V. Hematology. Are macrophages the bad guys in Hodgkin lymphoma? Nat Rev Clin Oncol 2010;7:301–302.
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A, Cabras A, . The germinal centre-derived lymphomas seen through their cellular microenvironment. Br J Haematol 2009;145:468–480.
   PubMed Web of Science ®Google Scholar
• Brune V, Tiacci E, Pfeil I, . Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med 2008;205:2251–2268.
   PubMed Web of Science ®Google Scholar
• Fonsatti E, Maio M, Altomonte M, . Biology and clinical applications of CD40 in cancer treatment. Semin Oncol 2010;37:517–523.
   PubMed Web of Science ®Google Scholar
• Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111–135.
   PubMed Web of Science ®Google Scholar
• Dadgostar H, Zarnegar B, Hoffmann A, . Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes. Proc Natl Acad Sci USA 2002;99:1497–1502.
   PubMed Web of Science ®Google Scholar
• van KC, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000;67: 2–17.
   PubMed Web of Science ®Google Scholar
• Berberich I, Shu GL, Clark EA. Cross-linking CD40 on B cells rapidly activates nuclear factor-kappa B. J Immunol 1994;153:4357–4366.
   PubMed Web of Science ®Google Scholar
• Coope HJ, Atkinson PG, Huhse B, . CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO J 2002;21:5375–5385.
   PubMed Web of Science ®Google Scholar
• Homig-Holzel C, Hojer C, Rastelli J, . Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and promotes lymphomagenesis. J Exp Med 2008;205: 1317–1329.
   PubMed Web of Science ®Google Scholar
• Hayden MS, Ghosh S. NF-kappaB in immunobiology. Cell Res 2011;21:223–244.
   PubMed Web of Science ®Google Scholar
• Travert M, Ame-Thomas P, Pangault C, . CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-kappaB activation and up-regulation of c-FLIP and Bcl-xL. J Immunol 2008;181:1001–1011.
   PubMed Web of Science ®Google Scholar
• Homig-Holzel C, Hojer C, Rastelli J, . Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and promotes lymphomagenesis. J Exp Med 2008;205: 1317–1329.
   PubMed Web of Science ®Google Scholar
• Fiumara P, Snell V, Li Y, . Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood 2001;98:2784–2790.
   PubMed Web of Science ®Google Scholar
• Gruss HJ, Hirschstein D, Wright B, . Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease. Blood 1994;84:2305–2314.
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Olivo K, Lorenzon D, . The role of interleukin-3 in classical Hodgkin's disease. Leuk Lymphoma 2005;46:303–311.
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Lorenzon D, Cattaruzza L, . Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer 2008;122:769–776.
   PubMed Web of Science ®Google Scholar
• Metkar SS, Naresh KN, Redkar AA, . CD40-ligation-mediated protection from apoptosis of a Fas-sensitive Hodgkin's-disease-derived cell line. Cancer Immunol Immunother 1998;47:104–112.
   PubMed Web of Science ®Google Scholar
• Zheng B, Fiumara P, Li YV, . MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 2003;102:1019–1027.
   PubMed Web of Science ®Google Scholar
• Kato M, Sanada M, Kato I, . Frequent inactivation of A20 in B-cell lymphomas. Nature 2009;459:712–716.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Hansmann ML, Bohle V, . TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009;206:981–989.
   PubMed Web of Science ®Google Scholar
• Longo CR, Arvelo MB, Patel VI, . A20 protects from CD40-CD40 ligand-mediated endothelial cell activation and apoptosis. Circulation 2003;108:1113–1118.
   PubMed Web of Science ®Google Scholar
• Graham JP, Arcipowski KM, Bishop GA. Differential B-lymphocyte regulation by CD40 and its viral mimic, latent membrane protein 1. Immunol Rev 2010;237:226–248.
   PubMedGoogle Scholar
• Eliopoulos AG, Young LS. LMP1 structure and signal transduction. Semin Cancer Biol 2001;11:435–444.
   PubMedGoogle Scholar
• Baxendale AJ, Dawson CW, Stewart SE, . Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth. Oncogene 2005;24:7913–7923.
   PubMed Web of Science ®Google Scholar
• Kis LL, Nishikawa J, Takahara M, . In vitro EBV-infected subline of KMH2, derived from Hodgkin lymphoma, expresses only EBNA-1, while CD40 ligand and IL-4 induce LMP-1 but not EBNA-2. Int J Cancer 2005;113:937–945.
   Google Scholar
• Kis LL, Gerasimcik N, Salamon D, . STAT6 signaling pathway activated by the cytokines IL-4 and IL-13 induces expression of the Epstein-Barr virus-encoded protein LMP-1 in absence of EBNA-2: implications for the type II EBV latent gene expression in Hodgkin lymphoma. Blood 2011;117:165–174.
   PubMed Web of Science ®Google Scholar
• Van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am J Pathol 1999;154:1685–1691.
   PubMed Web of Science ®Google Scholar
• Fischer M, Juremalm M, Olsson N, . Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer 2003;107:197–201.
   PubMed Web of Science ®Google Scholar
• Karnoub AE, Dash AB, Vo AP, . Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557–563.
   PubMed Web of Science ®Google Scholar
• Vaday GG, Peehl DM, Kadam PA, . Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 2006;66: 124–134.
   PubMed Web of Science ®Google Scholar
• Klein U, Casola S, Cattoretti G, . Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol 2006;7:773–782.
   PubMed Web of Science ®Google Scholar
• Tamura T, Tailor P, Yamaoka K, . IFN regulatory factor-4 and -8 govern dendritic cell subset development and their functional diversity. J Immunol 2005;174:2573–2581.
   PubMed Web of Science ®Google Scholar
• Shaffer AL, Emre NC, Romesser PB, . IRF4: Immunity. Malignancy! Therapy? Clin Cancer Res 2009;15:2954–2961.
   PubMed Web of Science ®Google Scholar
• Shaffer AL, Emre NC, Lamy L, . IRF4 addiction in multiple myeloma. Nature 2008;454:226–231.
   PubMed Web of Science ®Google Scholar
• Perez-Galan P, Mora-Jensen H, Weniger MA, . Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood 2011;117:542–552.
   PubMed Web of Science ®Google Scholar
• Gualco G, Weiss LM, Bacchi CE. MUM1/IRF4: a review. Appl Immunohistochem Mol Morphol 2010;18:301–310.
   PubMedGoogle Scholar
• Falini B, Fizzotti M, Pucciarini A, . A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000;95:2084–2092.
   PubMed Web of Science ®Google Scholar
• Re D, Hofmann A, Wolf J, . Cultivated H-RS cells are resistant to CD95L-mediated apoptosis despite expression of wild-type CD95. Exp Hematol 2000;28:31–35.
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Celegato M, Borghese C, . IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion. Br J Haematol 2011;152:182–190.
   PubMed Web of Science ®Google Scholar
• Jayanthan A, Howard SC, Trippett T, . Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737. Leuk Lymphoma 2009;50:1174–1182.
   PubMed Web of Science ®Google Scholar
• Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, . BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood 2002;100:3935–3941.
   PubMed Web of Science ®Google Scholar
• van Spronsen DJ, Peh SC, Vrints LW, . Clinical drug-resistant nodular sclerosing Hodgkin's lymphoma is associated with decreased bcl-2 expression in the surrounding lymphocytes and with increased bcl-2 expression in the Reed-Sternberg cells. Histopathology 2000;37:420–426.
   PubMed Web of Science ®Google Scholar
• Kim LH, Nadarajah VS, Peh SC, . Expression of Bcl-2 family members and presence of Epstein-Barr virus in the regulation of cell growth and death in classical Hodgkin's lymphoma. Histopathology 2004;44:257–267.
   PubMed Web of Science ®Google Scholar
• Saito M, Gao J, Basso K, . A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 2007;12: 280–292.
   PubMed Web of Science ®Google Scholar
• Xu D, Zhao L, Del VL, . Interferon regulatory factor 4 is involved in Epstein-Barr virus-mediated transformation of human B lymphocytes. J Virol 2008;82:6251–6258.
   PubMed Web of Science ®Google Scholar